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Objective: To characterize antimicrobial resistance patterns to amikacin (AN) and gentamicin (GM) among Gram- 
negative bloodstream isolates and to determine the possible relationship between use of AN and Gh'l and the occurrence 
of antibiotic resistance during a 6-year period. 
Methods: Standard media and techniques of isolation and identification were used. Antimicrobial susceptibility testing 
was performed with the disk diffusion method and API rapid ATE E strips. Data on consumption of aminoglycosides 
were collected by the central hospital pharmacy and were expressed as daily defined doses. 
Results: One thousand nine hundred and four bloodstream isolates were tested for AN and GM susceptibility between 
1989 and 1994. Activities of AN and GM remained high during the study period against most isolates of Gram-negative 
bacteria. No relationship could be observed between the use of AN/GM and the rate of AN/GM resistance. Nosocomial 
Gram-negative bloodstream isolates showed a higher degree of resistance towards both AN (3.9% of all nosocomial 
isolates) and GM (7.9%) than community-acquired isolates (1.8% toward AN and 3.1% towards GM, respectively). There 
was a significant increase (P=0.004) in the risk of GM resistance in patients with nosocomial Gram-i?egative bacteremia 
detected more than 14 days after admission. The proportion of GM-susceptible Pseudornonas aeruginosa isolates 
decreased linearly from 97% for infections acquired between day 3 and day 10 following admission to 80% for bacteremia 
developing 30 days or more after admission (P=0.008). 
Conclusions: AN and GM remain highly active antimicrobial drugs for treatment of GNB in times OF growing resistance 
to cephalosporins and fluoroquinolones. 
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INTRODUCTION 
Aminoglycoside antibiotics, alone or in combination 
with p-lactam antibiotics, are potent antimicrobial 
agents in the therapy of serious Gram-negative 
infections. Recent interest in the aminoglycosides has 
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demonstrated the advantage of once-daily dosing with 
respect to reduced toxicity and increased efficacy 
[1,2]. The reduced toxicity associated with once-daily 
dosing, in conjunction with the release of generic 
formulations onto the market in the near future, wiU 
probably lead to greater use of anlinoglycosides and 
re-attract the attention of physicians to this class of 
antibiotics. 
Moreover, the prevalence of aminoglycoside resist- 
ance has remained relatively low compared to that 
for cephalosporins or fluoroquinolones [3-6], and the 
emergence of bacterial resistance during therapy is 
rare [7]. However, several publications in the 1980s 
described increasing gentamicin (GM) resistance among 
Gram-negative pathogens which led to a changeover 
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from GM to amikacin (AN) as the principal formulary 
aminoglycoside in some centers or to an increase in the 
use of AN 18-12]. 
Awareness and survedlance of antimicrobial resist- 
ance patterns within an institution is crucial [13]. In this 
study, we characterized the secular trends in patterns of 
antimicrobial resistance to different aminoglycosides 
among Gram-negative bloodstream isolates and their 
possible relationship with aminoglycoside use during a 
6-year period. We also established the place of amino- 
glycosides in the treatment of patients with suspected 
or proven nosocomial Gram-negative bacteremia (GNB) 
in our institution, depending on the length of hospital 
stay at time of infection and the type of organism 
identified in blood cultures. 
METHODS 
Study objective and design 
The objective of the study was to characterize patterns 
of antimicrobial resistance to AN and GM among 
Gram-negative bloodstream isolates during a 6-year 
period. A secondary objective was to determine if any 
relationship between antibiotic resistance and the use of 
GM and AN could be observed. 
The study was conducted in the University 
Hospitals of Geneva (Hapitaux Universitaires de 
Genive (HUG)), Switzerland, a 1600-bed healthcare 
center providing primary and tertiary care for Geneva 
and the surrounding areas. Approximately 40 000 
patients are admitted annually for a mean length of stay 
of 11 days. 
We performed a 6-year retrospective study from 
1989 to 1994 to obtain information on all patients 
with GNB using data available from the HUG 
Information System, DIOGENE. These data included 
microbiological results with antimicrobial susceptibility 
testing, dates of admission, and dates of positive blood 
cultures. All hospitalized patients with a blood culture 
positive for an aerobic Gram-negative organism between 
1989 and 1994 were included in the study. All episodes 
of GNB were reviewed. 
We defined a patient with nosocomial bloodstream 
infection as one who had had at least one positive blood 
culture drawn at least 72 h after admission [14]. All 
episodes of bloodstream infection with different isolates 
were reviewed; only multiple episodes with the same 
isolate !?om the same patient were not considered for 
this analysis. 
Data on consumption of antimicrobials were 
collected by the central hospital pharmacy and are 
expressed as daily defined doses (DDD), one DDD 
being the normal adult daily dose of antimicrobial 
treatment. 
Microbiological methods 
Blood cultures were performed by inoculating 
approximately 20 mL of blood in equal parts into a 
Septi-Check Release vial (Becton Dickinson, Sparks, 
MD) and‘ a Signal vial (Oxoid, Basingstoke, UK) 
[15]. Standard me&a and techniques of isolation and 
identification were used [16]. Microorganisnls were 
categorized into 21 species. Antimicrobial susceptibihties 
on Enterobacteriaceae were determined routinely with 
the API rapid ATB E strips (BioMkieux, La Balme, 
France). This is a rapid (5 h) micro-dilution break- 
point method rendering comparable results to the 
disk diffusion method [17,18]. For all other Gram- 
negative bacteria, antimicrobial susceptibility testing 
was performed weekly with the disk difision method, 
and quality control was performed according to the 
National Committee for Clinical Laboratory Standards 
recommendations (NCCLS) [17]. Susceptibilities of 
Gram-negative bacteria to AN and GM were tested on 
a routine basis and comparison of resistance patterns 
was performed. Tobramycin susceptibility was not 
tested until mid-1993 in our laboratory; therefore, we 
excluded this aminoglycoside from the current analysis. 
Statistical analysis 
Linear trends were analyzed using simple linear 
regression analysis (least-squares method) with year as 
an independent variable and the number of Gram- 
negative bloodstream infection episodes or isolates, 
respectively, as dependent variables. For continuous 
variables, mean values were compared using two sample 
t-tests for independent samples. Differences in pro- 
portions were compared using either the chi-square 
test or Fisher’s exact test (for expected cell frequencies 
less than five). AU tests were two-sided and the level 
of statistical significance was set at 0.05. Data were 
analyzed using the computer software packages StatCalc 
(Epi-Info 5.0, Atlanta, Georgia, USA) and SYSTAT 
(version 5.2, Systat Inc., Evanston, lllinois, USA). 
Between 1989 and 1994, 233 156 patients were 
admitted at HUG, averaging 38 859 (2 630) patients 
a year (median 38732, range 37895-39955) and 
representing a total of 2 748 639 patient-days of care. 
Over this study period, 1997 bloodstream isolates were 
recovered &om 1835 episodes of bacteremia due to 
Gram-negative organisms. These included both com- 
munity and hospital-acquired bacteremias. 
Overall, activities of AN and GM against most 
isolates of Gram-negative bacteria remained high over 
the entire study period. The AN and GM resistance 
rates of Gram-negative bloodstream isolates were 5.3% 
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Table 1 Resistance to aminoglycosides of Gram-negative isolates involved in 1835 episodes of bacterenlia" 
Amikacin-R' (%) Gentamicin-R' ('A) P-value 
Community-acquired bacteria 1911054 (1.8) 3311055 (3.1) 0.049 
Nosocomial bacteremia 331848 (3.9) 67/849 (7.9) 0.001 
Early bacteremia (<15 days) 91384 (2.3) 191384 (4.9) 0.054 
Late bacteremia (215 days)b 241440 (5.4) 481442 (10.9) 0.003 
'One thousand nine hundred and ninety-seven bloodstream isolates were recovered fiom 1835 episodes of bacteremia. Results of 
susceptibhty testing were available for 1902 bloodstream isolates towards amikacin, and 1904 isolates towards gentamicin. 
bEarly episodes of nosocomial bacteremia were defined as those episodes that developed before hospital day 15; late episodes refer to those 
that developed 15 days or more after admission. 
Amikacin-R and gentamicin-R refer to resistance against the mentioned aminoglycosides. 
and 2.7%, respectively (P<O.O5). Nosocomial Gram- 
negative bloodstream isolates showed a higher degree 
of resistance towards both AN (3.9% of all noso- 
comial isolates) and GM (7.9%) than community- 
acquired isolates (1.8% towards AN and 3.1% towards 
GM, respectively; P < O . O O l ) .  Table 1 summarizes 
the observed differences between the patterns of 
susceptibility towards AN and GM of community 
and nosocomial Gram-negative bloodstream isolates 
recovered during the study period. 
AN was more active than GM against all Gram- 
negative bloodstream species that demonstrated some 
degree of resistance towards aminoglycosides. Marked 
differences in susceptibility patterns were noted for 
important pathogens: Pseudomonas aemginosa, Klebsietla 
spp., Serratia marcescens, and Acinetobacter spp. AN was 
the most effective antibiotic (97%), in both com- 
munity- and hospital-acquired Pseudomonar aeruginosa 
bloodstream isolates recovered during the study period; 
it remained significantly more active in nosocomial 
Table 2 Evolution of amikacin (AN) and gentamicin (GM) 
resistance among Gram-negative bloodstream isolates, trends 
HUG 1989-94" 
Year 
Resistance to 
Isolates fN) AN/GMb (%) 
1989 
1990 
1991 
1992 
1993 
1994 
268 0.5711.71 
284 0.1511.54 
273 1.0/1.33 
316 1.06/4.49 
292 0.6/6.61 
330 1.0414.02 
Total 1763 0.74/3.28 
'Analysis was conducted only for those Gram-negative bloodstream 
isolates responsible for more than 40 episodes during the study 
period (Escherichia coli, n=956; Enterobacter spp., n= 114; 
Haemophilus inyuenzae, n=58; Pseudomonas aeruginosa, n=201; 
Klebsiella spp., n=253; Proteus spp., n=666; Senatia marcescens, n=41; 
Salmonella spp., n=74). 
bThe observed trend for GM resistance was not statistically 
significant (P=O.O8, linear regression analysis). 
Pseudornonas aenrginosa bloodstream isolates (96%) 
than ceftazidime (92%), imipenem (83%), GM (89%), 
piperacillin-tazobactam (84%) and ciprofloxacin (90%). 
Additionally, whereas none of the Klebsiella spp. 
(n=253) or Serratia marcescens (n=41) bloodstream 
isolates were resistant to AN during the study period, 
GM resistance was seen among Serrai'ia marcescens (5/41, 
12.2%) and Klebsiella spp. (6/25.3, 2.4%) isolates. 
Concerning Klebsiella spp., we observed only four 
episodes of bacteremia due to extended-spectrum 
P-lactamase-producing K. pneumonl!e during the study 
period. One of the four ESBL isola1:es was sensitive to 
all tested aminoglycosides, whereas three were resistant 
to GM, but not to AN. 
The longer a patient had stayed in the hospital by 
the onset of bacteremia, the lugher was the risk of 
aminoglycoside resistance in nosocomial Pseudomonas 
aeruginosa bloodstream isolates. The proportion of GM- 
sensitive Pseudomonar aeruginosa isolates decreased linearly 
from 97% when infection was acquired between day 3 
and day 10 following admission to the hospital to 80% 
when bacteremia developed 30 days or more after 
admission (P=O.OOS, chi-square test for trends). In 
contrast, AN sensitivity decreased only fiom 100% 
(nosocomial acquisition between day 3 and day 10) to 
92% when Pseudomonas aetuginosa bacteremia developed 
after day 30. Table 1 gives additional information 
for nosocomial Gram-negative bbodstream isolates 
concerning resistance to aminoglycosides in relation 
to time of acquisition. In particular, we observed a 
significant increase ( F 0 . 0 0 4 )  in the risk of GM 
resistance in patients with nosoconual GNB detected 
more than 14 days after admission. 
Enterobacter spp. ( n z l l 4 )  were highly susceptible to 
both GM (97%) and AN (100%). Thii; stands in contrast 
to our findings concerning ceftazidixne (CAZ), where 
we observed a direct relationship between increasing 
CAZ use and increasing Enterobacttr spp. resistance. 
Comparison between resistance data  over the 6 years 
showed a significant decrease (r=0.82, P<0.05) in the 
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Table 3 Consumption of aminoglycosides and other relevant antimicrobials, HUG 1990-94 
Total amino- 
Period Arnikacin Gentaniicin Netilmicin Tobramycin glycosides Ceftriaxone Ceftazidirne lmipenem Ciprofloxacin 
1990 0.69 19.88 1.38 0.03 21.98 16.60 2.39 11.07 22.34 
1991 0.99 17.43 1.04 0.24 19.70 18.48 2.15 14.67 28.55 
1992 0.93 16.89 1.76 0.30 19.88 17.24 3.27 18.21 26.95 
1993 1.33 17.56 1.16 0.42 20.47 22.51 4.7s 15.56 31.92 
1994 1.45 13.60 0.71 1.21 16.97 17.63 3.79 13.85 27.86 
~~ ~ ~ 
Ddta are expressed in daily defined doses (DDD) per 1000 patient-days. Data for 1989 were not available. 
susceptibhty of Enterobacter spp. to CAZ (&om 100% 
(n=11) in 1989 to 77% (n=30) in 1994), whereas the 
strains remained sensitive to imipenem (loo%), AN 
(loo%), GM (97%), and ciprofloxacin (97%). 
Additional trended analyses were performed for 
Escherichia coli (total n=956; annual variation, 146- 
180), Klebsiella spp. (n=253; variation, 32-48) and 
Pseudomonas aeruginosa (n=201; variation, 22-50) 
bloodstream isolates, which did not show statistically 
significant decreases over time in susceptibhty patterns 
to the antimicrobials tested. The overall evolution over 
time of aminoglycoside resistance among all Gram- 
negative bloodstream isolates responsible for more than 
40 episodes of bacteremia is summarized in Table 2; the 
observed trend for GM resistance was not statistically 
significant (P=0.08). 
Table 3 summarizes the consumption patterns 
of aminoglycosides and other relevant antimicrobials 
during the study period; data for 1989 were not avail- 
able. As shown, overall aminoglycoside consumption 
decreased from 21.98 DDD/ 1000 patient-days (1 990) 
to 16.97 DDD/IOOO patient-days (1994) with GM as 
first-line aminoglycoside, followed by AN. Over time, 
the GM use declined from more than 90% (19.88 
DDD/1000 patient-days) of the total aminoglycoside 
consumption in 1990 to 80% (13.60 DDD/1000 
patient-days) in 1994. AN represented 7% or less of 
the total aminoglycoside use in the same period, with 
an increase from 0.69 (3%) DDD/1000 patient days in 
1990 to 1.45 (9%) in 1994. Analysis of correlation 
showed no significant change in prevalence of anti- 
microbial resistance in relation to the use of amino- 
glycosides. 
DISCUSSION 
Despite widespread use of aminoglycosides, develop- 
ment of resistance to this class of antibiotics remained 
low compared to other antimicrobial agents, as shown 
in a European study, where the large majority ofGram- 
negative bloodstream isolates were susceptible to amino- 
glycosides (90%) [19]. This observation was confirmed 
in the present study, where we found an even lower 
level of resistance and detected no significant change 
in overall GM or AN resistance of aerobic Gram- 
negative bloodstream isolates from 1989 to 1994. Thus, 
aminoglycosides are still extremely useful drugs in the 
treatment of most cases of Gram-negative sepsis, as 
reported by others [6,20,21]. 
Only a few studies have reported resistance data 
concerning Gram-negative bloodstream infections 
[6,19,22-241. Among these, Mylotte observed similar 
trends in resistance [24]. In his study, performed 
between 1977 and 1985, the yearly GM resistance rate 
of Gram-negative bloodstream isolates was 13.2% 
(range 6-18%), with no significant change over the 
study period. AN consumption represented less than 
11%, so AN resistance was only rarely observed in t h s  
study [24]. 
The literature on the relationship between the use 
of aminoglycosides and the development of resistance 
is rather controversial and complex [25-281. Some 
investigators reported increased AN resistance follow- 
ing unrestricted use of this compound [29-321. 
However, it is difficult to conclude from those studies 
whether the use of AN was the only incriminating 
factor. Other studies revealed no direct relationship 
between increased A N  use and enhanced resistance 
[8-121. Moreover, in some of these studies [8,27, 
33-35], increased use of AN seemed to be associated 
with a slight decrease in resistance to GM. Gerding 
et a1 [8] recently described an interesting policy in 
which aminoglycoside rotation was instituted, using 
AN extensively, if GM resistance increased. 
By differentiating community-acquired from noso- 
comial isolates, our study shows that the length of 
stay from admission to onset of bacteremia is a key 
parameter associated with an increased risk of GM 
resistance in nosocomial Pseudomonas aeruginosa isolates. 
Clinicians at our institution have been instructed to 
choose AN with another antipseudomonal agent in 
case of suspected nosocomial Pseudomonas aeruginosa 
bacteremia occurring 2 weeks or more afier admission. 
This recommendation is in accordance with other 
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published reports, where AN was found to be more 
active against Pseudomonas aemgdnosa isolates compared 
to GM, independent of the time of infection [6,10]. 
Whether tobramycin or AN has superior in vivo 
activity in the case of Pseudornonas spp. infections 
remains an open question [6,27,36]. 
This study has several limitations. First, the 
increasing use of broad-spectrum cephalosporins, carba- 
penems and fluoroquinolones in limiting or selecting 
AN/GM resistance among Gram-negative isolates 
was not evaluated and requires further investigation. 
Second, additional factors associated with the recovery 
of antibiotic-resistant bacteria, including device use, 
procedures, routes of transmission, and site of origin in 
case of secondary bloodstream infection, were not 
studied [25]. Third, it is possible that some of our data 
might have been influenzed by unrecognized epidemics 
of resistant Gram-negative bacteremia in our institution. 
Fourth, susceptibility results for other potentially useful 
aminoglycosides were not available for the entire study 
period. Tobramycin susceptibility was not tested until 
mid-1993 in our laboratory. Based on susceptibility 
patterns observed, tobramycin offered no significant 
advantage over GM: resistance towards both GM and 
tobramicin was almost universal. The only exception 
was the possible higher activity of tobramycin against 
Acinetobacter baumannii. 
Finally, the shortness of the study period may 
explain the lack of change in resistance. Results in the 
literature strongly suggest that aminoglycoside resistance 
is related to use over a long time period [28]. Addi- 
tionally, it is possible that the change in aminoglycoside 
use over time was not drastic enough to cause any 
important change in susceptibility patterns. 
In summary, this study represents one of the largest 
series in the literature concerning resistance data on 
Gram-negative bloodstream isolates and related amino- 
glycoside use. It shows that AN resistance among 
Gram-negative bloodstream isolates was rare at this 
center and that, despite predominant use of GM, there 
was no clinically important change in GM resistance 
rates and patterns during the study period. Although 
new p-lactam agents and fluoroquinolones share a 
similar antibacterial spectrum towards aerobic Gram- 
negative bacteria, the efficacy of aminoglycosides and 
resistance problems with the newer drugs suggest a 
continued need for aminoglycosides. 
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